| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
5 companies
Invus Public Equities, L.P. last filed a Form 4 in December 2024, as Director, 10% Owner at LXRX. The filings on record cover 5 companies.
Our model assigns Invus Public Equities, L.P. a strong insider score of 78/100, based on 26 past trades. Over a 12-month horizon, 80.8% of those trades were profitable, with an average 12-month return of +40.5%.
At the last filing, the largest reported position was 9,250,005 shares of SRRK. Net of sales, the SRRK filings show accumulation of 499,971 shares.
Invus Public Equities, L.P. has 30 Form 4 filings on record from November 2017 to December 2024, across 5 companies: 10% Owner at Scholar Rock (SRRK), 2022–2024; 10% Owner at Crescent Biopharma (CBIO), 2023–2024; 10% Owner at Seer (SEER), 2020–2021, and 2 more.
The 63 reported transactions were 44 open-market purchases, 17 open-market sales and 2 conversions.
Counted by filing, the open-market trades come to 22 purchases worth about $117.7M and 8 sales worth about $99.1M.
The largest open-market purchase was 10,937,500 shares of LXRX at an average $3.20 on December 16, 2020, about $35.0M.
The largest open-market sale was 1,600,000 shares of SRRK at an average $41.65 on December 10, 2024, about $66.6M. Twelve months later SRRK was up 1%.
None of the 6 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from December 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2024 | SRRK Scholar Rock Holding Corp | 10% Owner | Sell | 1,600,000 | $41.65 | $66,640,000.00 | -14.7% | -21.0% | +1.2% | |
| Nov 25, 2024 | SRRK Scholar Rock Holding Corp | 10% Owner | Sell | 409,433 | $38.49 | $15,757,638.99 | -3.6% | -1.5% | +9.9% | |
| Aug 8, 2024 | CBIO Crescent Biopharma, Inc. | 10% Owner | Sell | 322,361 | $0.19 | $61,206.32 | -4.9% | +100.7% | -31.5% | |
| Aug 6, 2024 | CBIO Crescent Biopharma, Inc. | 10% Owner | Sell | 220,255 | $0.19 | $41,183.94 | -3.2% | +128.8% | -38.6% | |
| Aug 2, 2024 | CBIO Crescent Biopharma, Inc. | 10% Owner | Sell | 349,764 | $0.20 | $71,097.02 | -4.9% | +100.4% | -40.9% | |
| Jul 30, 2024 | CBIO Crescent Biopharma, Inc. | 10% Owner | Sell | 1,379,119 | $0.23 | $315,261.62 | -16.1% | -22.8% | -42.2% | |
| Oct 12, 2023 | SRRK Scholar Rock Holding Corp | 10% Owner | Buy | 2,199,931 | $6.86 | $15,086,735.66 | +24.3% | +106.0% | +228.9% | |
| Apr 28, 2023 | SRRK Scholar Rock Holding Corp | 10% Owner | Buy | 31,557 | $6.43 | $202,845.24 | +0.3% | +6.7% | +127.0% | |
| Feb 24, 2023 | CBIO Crescent Biopharma, Inc. | 10% Owner | Buy | 100,000 | $1.70 | $170,000.00 | +1.2% | +3.0% | +71.6% | |
| Feb 23, 2023 | CBIO Crescent Biopharma, Inc. | 10% Owner | Buy | 400,000 | $1.78 | $712,255.00 | +4.9% | +5.3% | +69.6% |